Want better coverage for anti-obesity medications?
The 2025 RFI for ways to deregulate and improve the health of America has ended. If you didn’t get a request submitted in time – that’s OK! The US government is designed to be for the people, which means there is a way that you can have your voice heard at any time – that doesn’t require you to fly to DC and hound legislators or march around with picket signs.
All you have to do is sit at your computer for a few minutes and fill out a form.
It’s a bit clunky, but it’s not hard – at all!
We can all be advocates – right now!
It’s not hard or time-consuming!
Click HERE to go to the HHS Deregulation Website:
Sample text for submission:
Box #1: Which agency/agencies promulgated the regulation?
Centers for Medicare & Medicaid Services (CMS), under HHS
Box #2: Which title, parts, and/or sections of the Code of Federal Regulations (C.F.R.) should be rescinded?
42 C.F.R. § 423.100 – Prohibition on coverage of anti-obesity drugs under Part D
Box #3: What is your name?
This one is all you – I’ve already submitted one under my name!
Box #4: Choose the Type of Rescission
Notice of Proposed Rulemaking
Box #5: What is the name of the regulation being rescinded, if applicable?
Medicare Part D Anti-Obesity Drug Coverage Exclusion
Box #6: Please provide a short summary of the justifications for the rescission.
This exclusion denies medically necessary treatment for the disease of obesity. Covering evidence-based medications supports public health, reduces downstream costs, and aligns with chronic disease management principles.
Box #7: Please insert the address of the agency.
U.S. Department of Health and Human Services
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Box #8: Please insert the contact information for the agency.
CMS Office of Strategic Operations and Regulatory Affairs
Phone: 202‑690‑7118
Email: regs@cms.hhs.gov
Box #9: What is the background for the regulation being rescinded?
Part D’s exclusion of anit-obesity medications dates back to initial benefit design. Despite FDA approval and clinical necessity, coverage remains prohibited unless prescribed for another condition (e.g., diabetes).
Box #10: Explain the reasons for the rescission.
• Contradicts medical necessity of obesity treatment
• Increases health disparities
• Denies patients access to proven therapies
Box #11: Describe the text of the relevant C.F.R. provisions as it will exist after the rescission.
Remove 42 C.F.R. § 423.100 exclusions; remaining Part 423 provisions intact and renumbered.
Box #12: Please insert the name of the current agency head.
Dr. Mehmet Oz
Box #13: Please insert the title of the agency head.
Administrator, Centers for Medicare & Medicaid Services